Silexion Therapeutics Corp (SLXN)
SLXNNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$3.27
+0.6526 (+24.97%) today
At the close, Nov 11, 4:00 PM ET. After hours $3.22 -0.31%
- Market cap
- $49.14m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $2.70 to $3.88
- 52-week range
- $2.57 to $777.06
- Average volume
- 531.0k
- Previous close
- $2.61
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.29m | -$4.41m | -$2.75m | -$3.68m |
| Net income | -$3.26m | -$4.41m | -$2.73m | -$3.55m |
News
8 latest- Silexion Sets 1-For-24 Reverse Share Split To Regain Nasdaq Compliance RTTNews · 2 days ago
- Silexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer RTTNews · Sep 30, 2026
- Biotech Stocks On The Move - SLXN, SMMT, IOVA, NTHI RTTNews · Sep 29, 2026
- Silexion Advances SIL204 With Positive Findings On Systemic Uptake In KRAS-Driven Cancers RTTNews · Sep 28, 2026
- 5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus RTTNews · Sep 10, 2026
- Silexion Posts Wider Q2 Loss On Higher SIL-204 Development Costs RTTNews · Sep 4, 2026
- Silexion Prices $2.5 Million Offering To Advance SIL204 Clinical Trial, Stock Down RTTNews · Aug 12, 2026
- German BfArM Clears Silexion's Phase 2/3 Trial For SIL-204 In Pancreatic Cancer; Stock Down RTTNews · Jun 24, 2026
The company
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- silexion.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.